



FOR IMMEDIATE RELEASE

CONTACT

Noel Brown
919-313-2888
n.brown@hemobioscience.com

Hemo bioscience Receives FDA Clearance to Market C3 Complement Control Cells

Durham, N.C. (November 7th 2012) – Hemo bioscience Inc, reports that it has received U.S. Food and Drug Administration (FDA) 510k clearance for its complement coated control cells under BK 120022. Hbs brand C3 Control Cells can be used as a control to confirm the efficacy of the AHG reagent used during Direct and Indirect Anti-Globulin Tests. Hemo bioscience performs lot release of its C3 Control Cells with a wide range of FDA licensed Anti-C3 Human Globulin.

“We are pleased to have received clearance to market our new C3 Control Cells.” said Hemo bioscience President and CEO Noel R. Brown, “A strategic decision was made to begin development of our complete red cell product line starting with complement control cells. We will continue to develop, manufacture, and deliver high value products to the U.S. blood bank market as the company grows.”

Founded in 2003, Hemo bioscience Inc. manufactures and distributes blood typing reagents and ancillary products used by hospitals, reference laboratories and donor centers in the area of compatibility testing. Hemo bioscience plans to have a complete line of reagents available for all targeted market segments. www.hemobioscience.com

###